{"filing":{"accession_number":"0001372514-26-000077","cik":"0001372514","ticker":"KPHMW","company_name":"KIORA PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-08-19","report_date":"2026-08-19","primary_document":"kprx-20260819.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000077/kprx-20260819.htm"},"events":[{"id":28382,"run_id":25957,"accession_number":"0001372514-26-000077","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"Kiora Pharmaceuticals entered into an Exclusive License and Development Agreement with Chong Kun Dang Pharmaceutical Corporation granting exclusive rights to develop, manufacture, and commercialize KIO-301 in South Korea. The transaction includes an upfront payment of $1.0 million, milestone payments, and double-digit royalties, expanding Kiora's global commercialization network for this clinical-stage molecular photoswitch.","company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPHMW","filing_date":"2026-08-19","form":"8-K","submitted_at":null,"items":[{"id":30311,"accession_number":"0001372514-26-000077","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Kiora Pharmaceuticals entered into an Exclusive License and Development Agreement with Chong Kun Dang Pharmaceutical Corporation granting exclusive rights to develop, manufacture, and commercialize KIO-301 in South Korea. This is a material definitive agreement involving the licensing of a key product asset (KIO-301, a clinical-stage molecular photoswitch) to a strategic partner, with upfront payment of $1.0 million, milestone payments, and double-digit royalties. The transaction expands Kiora's global commercialization network and is material to investors assessing the company's development strategy and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T11:02:40.727369+00:00","company_name":"","ticker":null,"filing_date":""},{"id":30312,"accession_number":"0001372514-26-000077","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Kiora Pharmaceuticals announced the licensing of development and commercialization rights for KIO-301 in South Korea to Chong Kun Dang Pharmaceutical Corporation, with a $1 million upfront payment and eligibility for milestone and royalty payments. This is a material strategic partnership and licensing transaction that expands the company's development and commercialization network for a key pipeline asset across a major global market, but does not constitute a traditional M\u0026A activity (acquisition, merger, or change of control). The event is clearly operational/strategic in nature and material to investors assessing the company's pipeline advancement and commercialization strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T11:02:40.727369+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30311,"accession_number":"0001372514-26-000077","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Kiora Pharmaceuticals entered into an Exclusive License and Development Agreement with Chong Kun Dang Pharmaceutical Corporation granting exclusive rights to develop, manufacture, and commercialize KIO-301 in South Korea. This is a material definitive agreement involving the licensing of a key product asset (KIO-301, a clinical-stage molecular photoswitch) to a strategic partner, with upfront payment of $1.0 million, milestone payments, and double-digit royalties. The transaction expands Kiora's global commercialization network and is material to investors assessing the company's development strategy and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T11:02:40.727369+00:00","company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPHMW","filing_date":"2026-08-19"},{"id":30312,"accession_number":"0001372514-26-000077","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Kiora Pharmaceuticals announced the licensing of development and commercialization rights for KIO-301 in South Korea to Chong Kun Dang Pharmaceutical Corporation, with a $1 million upfront payment and eligibility for milestone and royalty payments. This is a material strategic partnership and licensing transaction that expands the company's development and commercialization network for a key pipeline asset across a major global market, but does not constitute a traditional M\u0026A activity (acquisition, merger, or change of control). The event is clearly operational/strategic in nature and material to investors assessing the company's pipeline advancement and commercialization strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T11:02:40.727369+00:00","company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPHMW","filing_date":"2026-08-19"}]}